SCHEMBL685123

SCHEMBL685123

Cc1cc(N)nc(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL105871 0.81
SCHEMBL2735686 0.81
SCHEMBL28995570 0.75
SCHEMBL501790 0.74
SCHEMBL94111 0.74
SCHEMBL31324837 0.74
SCHEMBL25198744 0.72
Bromide SCHEMBL5755666 0.72 NOS2 (0.95)
SCHEMBL17923105 0.70
SCHEMBL13536723 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459932-B2 KIF18A inhibitors AMGEN INC. (US) 2025-11-04 US disclosed
US-12441736-B2 KIF18A inhibitors AMGEN INC. (US) 2025-10-14 US disclosed
EP-3898592-B1 HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS AMGEN INC (US) 2024-10-09 EP disclosed
EP-4085059-B1 HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME ACCRO BIOSCIENCE HK LTD (HK) 2024-03-20 EP disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 WO disclosed
EP-3897855-B1 KIF18A INHIBITORS AMGEN INC (US) 2023-06-07 EP disclosed
EP-3897855-B1 KIF18A INHIBITORS AMGEN INC (US) 2023-06-07 EP disclosed
US-20230151432-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES AMGEN INC. (US) 2023-05-18 US disclosed
US-20230151432-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES AMGEN INC. (US) 2023-05-18 US disclosed
US-20230151432-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES AMGEN INC. (US) 2023-05-18 US disclosed
US-8785454-B2 Heterocyclic compounds and uses thereof INTELLIKINE LLC (US) 2014-07-22 US disclosed
WO-2014076091-A1 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-22 WO disclosed
US-20140120083-A1 TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS INFINITY PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8703777-B2 Certain chemical entities, compositions and methods INTELLIKINE LLC (US) 2014-04-22 US disclosed
US-20140088099-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION INFINITY PHARMACEUTICALS, INC. (US) 2014-03-27 US disclosed
WO-2014004470-A1 TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS INFINITY PHARMACEUTICALS, INC. (US) 2014-01-03 WO disclosed
US-8569323-B2 Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof INTELLIKINE, LLC (US) 2013-10-29 US disclosed
US-8106064-B2 administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-01-31 US disclosed
US-20110281866-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE, INC. (US) 2011-11-17 US disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 US disclosed